目的 對(duì)酒泉市人民醫(yī)院兒科門(mén)診注射用單磷酸阿糖腺苷的使用情況進(jìn)行分析，為臨床安全、合理用藥提供參考。方法 統(tǒng)計(jì)酒泉市人民醫(yī)院2016年8~10月兒科門(mén)診使用注射用單磷酸阿糖腺苷的處方，對(duì)患兒的年齡、疾病診斷、注射用單磷酸阿糖腺苷的用量、療程和聯(lián)合用藥等進(jìn)行統(tǒng)計(jì)分析。結(jié)果 注射用單磷酸阿糖腺苷的使用率高達(dá)59.08%；使用患兒中，年齡最小的為5 d，最大的13歲。以上呼吸道感染使用率最高，達(dá)46.29%；使用劑量最低為0.05 g/d，最大為0.3 g/d，療程多為1~3 d；單用注射用單磷酸阿糖腺苷占41.25%，其余均為聯(lián)合用藥，聯(lián)合用藥比例達(dá)58.75%。結(jié)論 酒泉市人民醫(yī)院門(mén)診注射用單磷酸阿糖腺苷的使用存在超適應(yīng)癥用藥、用藥劑量過(guò)大、過(guò)度聯(lián)合用藥等問(wèn)題，應(yīng)采取積極措施進(jìn)行干預(yù)。

Objective To analyze the usage of Vidarabine Monophosphate for injection in outpatient Department of Pediatrics of Jiuquan People's Hospital, and provide reference for clinical safety as well as rational drug use. Methods The prescriptions of using Vidarabine Monophosphate for injection in outpatient Department of Pediatrics of Jiuquan People's Hospital from June to August in 2016 were calculated, and children's age, diagnosis, and dosage, course, and combination of Vidarabine Monophosphate for injection were analyzed. Results The usage rate of Vidarabine Monophosphate for injection was up to 59.08%. The youngest child was 5 d, and the oldest child was 13 years old. The children with upper respiratory tract infection had the highest utilization rate, which was up to 46.29%. The minimum dose was at 0.05 g/d, and the maximum dose was at 0.3 g/d. Most course of treatment lasted from 1 d to 3 d. Single-use of Vidarabine Monophosphate for injection accounted for 41.25%, and the rest were drug combination with the combination ratio at 58.75%. Conclusion The usage of Vidarabine Monophosphate for injection in Jiuquan People's Hospital has presented several problems such as off-label use, excessive dosage of medication, and drug combination overage, thus positive interventions should be taken.